Sopharma AD
Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/2014
22-06-2026 13:42:32
Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/2014
22-06-2026 13:42:32
Sofia, Bulgaria, June 22, 2026 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for May 2026 the Company recorded an increase in sales of 88% compared to the same month of the previous year, incl. 46% increase in domestic sales and 118% increase in export sales.
For the period from the beginning of 2026, the Company achieved sales growth of 41%, including a 6% decrease in domestic sales and a 70% growth in export sales.
- Attachments:
-
Notification for sales revenues for May 2026


